


GENERATION OF MATURE IPSC-DERIVED CAR T CELLS WITH ENHANCED ANTITUMOR ACTIVITY VIA EPIGENETIC REPROGRAMMING

Ran Jing, Ph.D.

The George Daley Laboratory

Boston Children's Hospital/Harvard Medical School


Current CAR T cell therapy



Autologous T cells:

- No graft rejection
- No graft-vesushost disease (GVHD)
- Impaired Starting material
- Heterogeneous drug product
- Complex logistic
- Time consuming/Expens ive


Human pluripotent stem cells for CAR T cell therapy



iPSC-T cells:


- Health Starting material
- Homogeneous drug product
- Simple logistic
- Cost-effective
- Efficient differentiation into mature T cells?

Generation of T cells from iPSCs




Shah et al, 2014

Generation of T cells from iPSCs




- Co-culture with mouse stromal cells (OP9-DLL1/DLL4)
- Cytokines: IL-7. SCF, Flt3
 Low efficiency
 T cells with innate (γδ-like) phenotypes (Themeli et al., 2013)
- 3D organoid (Vizcardo et al., 2018, Montel-Hagen et al., 2019)
- Stroma-free (Shukla et al., 2017, Iriguchi et al., 2021)

Identification of new regulators for T cell differentiation




Identification of new regulators for T cell differentiation



Nature. 2018 Jan 25;553(7689):506-510. doi: 10.1038/nature25435. Epub 2018 Jan 17.


Regulation of embryonic haematopoietic multipotency by EZH1.

 $\underline{\text{Vo LT}^{1,2,3}, \text{Kinney MA}^{1,2}, \underline{\text{Liu }} \underline{X}^4, \underline{\text{Zhang Y}^{4,5}, \underline{\text{Barragan J}^{1,2}}, \underline{\text{Sousa PM}^{1,2}, \underline{\text{Jha DK}^{1,2}, \underline{\text{Han A}^{1,2}, \underline{\text{Cesana M}^{1,2}, \underline{\text{Shao Z}^5}, \underline{\text{North TE}^6}, \underline{\text{Orkin SH}^{2,3,7}, \underline{\text{Doulatov S}^8, \underline{\text{Xu J}^4, \underline{\text{Daley GQ}^{1,2,3}}}}}$





Stroma-free T cell differentiation from iPSCs







iPSC-derived T cells exhibit mature T cell phenotypes









EZ-T cells exhibit molecular signatures of PBMC $\alpha\beta$ T cells









EZ-T cells display a highly diverse TCR repertoire


TCRBV gene usage:




EZ-T cells display a highly diverse TCR repertoire

CDR3 length:







EZ-T cells give rise to effector and memory-like subsets upon activation




EZ-T cells give rise to effector and memory-like subsets upon activation



EZ-T cells give rise to effector and memory-like subsets upon activation



CAR-transduced EZ-T cells display enhanced effector functions than control iPSC-T cells




CD19-41BBz

EF1a CD19-ScFv CD8 TM 4-1BB CD3z T2 mCherry


CAR-transduced EZ-T cells display enhanced effector functions than control iPSC-T cells

Cytotoxic assay:




CAR-transduced EZ-T cells display enhanced effector functions than control iPSC-T cells







CD19 CAR EZ-T cells display superior anti-tumor activity in vivo





CD19 CAR EZ-T cells display superior anti-tumor activity in vivo



CD19 CAR EZ-T cells display superior anti-tumor activity in vivo








SUMMARY:

- A stroma-free system for efficient production of mature iPSC-T cells expressing diverse TCRs
- EZH1 repression-mediated epigenetic reprogramming generates mature EZ-T cells similar to peripheral blood TCRαβ T cells
- EZ-T cells can give rise to memory-like T cells upon activation.
- CAR EZ-T cells display enhanced antitumor activity in vitro and in vivo



Acknowledgement







Daley Lab North Lab Schlaeger Lab **George Daley** Trista North Thorsten Schlaeger Mohamad Ali Areum Han Caroline Kubaczka Deepak Jha Michael Sanborn John Atwater Mariam Hachimi









MASSACHUSETTS GENERAL HOSPITAL

Maus Lab Marcela Maus Irene Scarfo